

# Bioventix PLC (BVXP:LN)



**London**  
Stock Exchange

Health Care/Biotechnology

Price: 16.75

Report Date: May 29, 2026

## Business Description and Key Statistics

Bioventix plc is a United Kingdom-based company specializing in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, such as automated immunoassays used in blood testing. The antibodies created at the Company are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. It offers a portfolio of antibodies to customers for both commercial use and research and development purposes, for the diagnosis or monitoring of a range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. The Company's products include sheep monoclonal antibodies (SMAs), Pyrene (HOP-G) ELISA Kits, and Pyrene (HOP-G) Lateral Flow Kits. The Company supplies antibody products and services to the majority of multinational clinical diagnostics companies.

**Website:** <https://www.bioventix.com/>

**ICB Industry:** Health Care

**ICB Subsector:** Biotechnology

**Address:** 7 ROMANS BUSINESS PARK EAST STREET  
FARNHAM GU9 7SX  
GBR

**Employees:** 16

	Current	YTY % Chg
<b>Revenue LFY (M)</b>	13	-8.2
<b>EPS Diluted LFY</b>	1.45	-6.2
<b>Market Value (M)</b>	88	
<b>Shares Outstanding LFY (000)</b>	5,225	
<b>Book Value Per Share</b>	2.11	
<b>EBITDA Margin %</b>	78.00	
<b>Net Margin %</b>	59.3	
<b>Long-Term Debt / Capital %</b>	0.0	
<b>Dividends and Yield TTM</b>	1.50 - 8.96%	
<b>Payout Ratio TTM %</b>	100.0	
<b>60-Day Average Volume (000)</b>	12	
<b>52-Week High &amp; Low</b>	30.20 - 13.75	
<b>Price / 52-Week High &amp; Low</b>	0.55 - 1.22	

## Price, Moving Averages & Volume



Bioventix PLC is currently trading at 16.75 which is 1.0% above its 50 day moving average price of 16.58 and 13.5% below its 200 day moving average price of 19.36.

BVXP:LN is currently 44.5% below its 52-week high price of 30.20 and is 21.8% above its 52-week low price of 13.75. Over the past 52-weeks, BVXP:LN is down 42.7% while on a calendar year-to-date basis it is down 12.1%.

The Relative Strength Index (RSI) indicator for BVXP:LN is currently 47.68. An RSI value of 70 and above is considered overbought and 30 and below oversold.

# Bioventix PLC (BVXP:LN)



**London**  
Stock Exchange

Health Care/Biotechnology

Price: 16.75

Report Date: May 29, 2026

## Price Performance, Technical Indicators & Risk Metrics

Price Performance	% Change	Difference vs FTSE 350	Technical Indicators	
1-Day %	0.00	0.10	50-Day Average Price	16.58
1-Week %	1.52	1.59	Price / 50-Day Average	1.01
4-Week %	0.00	-2.30	200-Day Average Price	19.36
52-Week %	-42.74	-60.54	Price / 200-Day Average	0.87
Quarter-to-Date %	11.67	8.56	RSI - Relative Strength Index	47.68
Year-to-Date %	-12.07	-16.81	<b>Risk Metrics</b>	
Last Month %	15.00	12.61	Price Volatility	0.20
Last Quarter %	-21.26	-22.84	Sharpe Ratio	-0.16
Last Calendar Year %	-40.00	-59.92	Sortino Ratio	-0.26

## 5-Year Price Performance vs. FTSE 350

**Bioventix PLC**  
**FTSE 350 Index**

Current: 0.40 CAGR: -16.9%  
Current: 1.39 CAGR: 6.8%



Over the past five years, Bioventix PLC's stock price is down 60.1% which is 98.7% below the FTSE 350 Index performance of 38.6% over the same period. Bioventix PLC's cumulative annualized growth rate (CAGR) over the five year period has been -16.9% while that of the FTSE 350 Index has been 6.8%.

Over the past year, Bioventix PLC's stock price performance of -42.7% has underperformed that of the FTSE 350 Index by 60.5%. On a year-to-date basis, Bioventix PLC's stock price performance of -12.1% has underperformed the FTSE 350 Index by 16.8%.

Over the past week, Bioventix PLC's stock price performance of 1.5% has outperformed that of the FTSE 350 Index by 1.6%.

# Bioventix PLC (BVXP:LN)




Health Care/Biotechnology

Price: 16.75


Report Date: May 29, 2026

## Growth and Profitability Metrics


Historical Growth	3-Year	5-Year	10-Year	Profitability	Current	5-Year Average	10-Year Average
Revenues %	-0.9	4.2	10.1	Gross Margin %	92.4	92.8	92.5
Revenues Per Share %	-0.9	4.1	9.9	EBITDA Margin %	78.0	77.5	77.6
EBITDA %	-1.6	4.9	10.7	Pre-Tax Margin %	78.9	77.8	77.8
EPS Diluted %	-4.0	1.9	9.7	Net Margin %	59.3	62.1	65.0
Free Cash Flow %	-0.9	2.7	9.8	Return on Equity %	65.1	68.4	63.6
Cash from Operations %	-0.8	2.3	9.7	Return on Capital %	65.5	69.2	64.5
Book Value %	1.7	1.3	4.4	Return on Assets %	57.5	61.9	58.8




Bioventix PLC's cumulative annualized revenue growth rate over the charted period is 4.7%. This compares to cumulative annualized growth of -0.9% over the past 3 years.



Bioventix PLC's cumulative annualized EPS growth rate over the charted period is 3.2%. This compares to cumulative annualized growth of -4.0% over the past 3 years.



Bioventix PLC's net profit margin of 59.3% is 2.8% below the period's mean net margin of 62.1%. During the charted period, the observed net profit margin high and low were 65.5% and 58.0% respectively.



Bioventix PLC's return on equity of 65.1% is 3.3% below the period's mean return on equity of 68.4%. During the charted period, the observed ROE high and low were 76.1% and 59.3% respectively.

# Bioventix PLC (BVXP:LN)




Health Care/Biotechnology

Price: 16.75


Report Date: May 29, 2026

## Valuation Metrics

	Current	5-Year Median	10-Year Median		Current	5-Year Median	10-Year Median
Price / EPS TTM	11.8	24.0	25.0	Earnings Yield %	8.44	4.16	4.00
Price / Sales	7.0	15.5	16.3	Free Cash Flow Yield %	4.41	2.00	1.91
Price / Operating Cash Flow	11.8	23.8	24.9	Dividend Yield %	8.96	4.03	2.82
Price / Book Value	7.9	16.4	16.1	Enterprise Value / EBITDA	8.4	19.0	19.8



Bioventix PLC is trading at 11.84 times its EPS generated during the latest fiscal year. This multiple is below the historically observed median of 24.02, while high and low observations have been 33.02 and 9.72.



Bioventix PLC is trading at a Price to Sales ratio of 7.02 based on sales generated during the latest fiscal year. This ratio is below the historically observed median ratio of 15.54, while high and low observations have been 20.82 and 5.77.



Bioventix PLC is trading at a Price to Book ratio of 7.93 based on book value at the latest fiscal year end. This ratio is below the historically observed median of 16.44, while high and low observations have been 22.82 and 6.51.



Bioventix PLC has a Free Cash Flow Yield of 4.41% based on free cash flow generated during the latest fiscal year. This value is above the historically observed median yield of 2.00%, while high and low observations have been 5.37 and 1.37.

# Bioventix PLC (BVXP:LN)



Health Care/Biotechnology

Price: 16.75

Report Date: May 29, 2026

## Dividends Data

Dividends Per Share TTM		1.50	Payout Ratio TTM %		100.00%	Dividend Yield TTM %		8.96%
Rate	Ex Date	Record Date	Payment Date	Currency	Note			
0.700	09-04-2026	10-04-2026	24-04-2026	GBP				
0.800	06-11-2025	07-11-2025	21-11-2025	GBP				
0.700	10-04-2025	11-04-2025	25-04-2025	GBP				
0.870	07-11-2024	08-11-2024	21-11-2024	GBP				
0.680	11-04-2024	12-04-2024	26-04-2024	GBP				
0.900	09-11-2023	10-11-2023	24-11-2023	GBP				
0.620	06-04-2023	11-04-2023	21-04-2023	GBP				
0.740	03-11-2022	04-11-2022	18-11-2022	GBP				
0.520	07-04-2022	08-04-2022	22-04-2022	GBP				
0.380	28-10-2021	29-10-2021	12-11-2021	GBP				
0.620	28-10-2021	29-10-2021	12-11-2021	GBP				
0.430	08-04-2021	09-04-2021	23-04-2021	GBP				

## Dividend Growth and Yield



Bioventix PLC's trailing 12-month dividend per share is 1.50 and its dividend has grown at a cumulative annualized rate of 10.7% over the charted period. This compares to dividend growth of -4.50% over the past year and cumulative annualized growth of 3.30% over the past 3 years.



Bioventix PLC's current dividend yield is 8.96% based on trailing 12 month dividends. The current yield is above the historically observed median of 4.03% and, over the charted time period, the observed high yield has been 10.91% and the observed low yield has been 2.10%.

# Bioventix PLC (BVXP:LN)




Health Care/Biotechnology

Price: 16.75


Report Date: May 29, 2026

## ICB Subsector Peer Comparisons


### Price Change Year to Date %




### Price Change Last Calendar Year %




### Price / EPS TTM




### Price / Book Value



### EPS 5-Year Growth Rate %



### Revenue 5-Year Growth Rate %



# Bioventix PLC (BVXP:LN)



London  
Stock Exchange

Health Care/Biotechnology

Price: 16.75

Report Date: May 29, 2026

## Abbreviations:

<b>CAGR</b>	- Cumulative annual growth rate.
<b>EBIT</b>	- Earnings before interest and taxes.
<b>EBITDA</b>	- Earnings before interest, taxes, depreciation & amortization.
<b>LFY</b>	- Last fiscal year
<b>M</b>	- Million
<b>LON</b>	- London Stock Exchange

## Definitions:

**Market Value** - Weekly Price times latest Shares Outstanding times any applicable ADR factor.

**Revenue** - Sum of the last four quarters of Revenues.

**Revenue Per Share** - Sum of the last four quarters of Total Revenue divided by Weighted Average Shares Outstanding.

**Normalized EPS LFY**- EPS excluding non-recurring, non-operating items, fiscal year aligned TTM value.

**60-Day Average Volume (000)** - The average of the last 60 daily volume values in thousands of shares.

**Price 52-Week High** - The high closing price from the last 52 weeks of daily closing prices.

**Price 52-Week Low** - The low closing price from the last 52 weeks of daily closing prices.

**Price / 52-Week High** - Latest price divided by the high price from the past 52 weeks of daily closing prices.

**Price / 52-Week Low** - Latest price divided by the low price from the past 52 weeks of daily closing prices.

**50-Day Average Price** - Mean of last 50 daily closing prices.

**200-Day Average Price** - Mean of last 200 daily closing prices.

**Price / 50-Day Average Price** - Latest closing price divided by mean of last 50 daily closing prices, as a percentage.

**Price / 200-Day Average Price** - Latest closing price divided by mean of last 200 daily closing prices, as a percentage.

**Relative Strength Index** - Relative Strength Index or RSI measures the magnitude of gains over a given time period against the magnitude of losses over that period. The equation is  $RSI = 100 - 100 / (1 + RS)$  where  $RS = (\text{total gains} / n) / (\text{total losses} / n)$  and  $n = \text{number of RSI periods}$ . In this item, 14 days is used and one year of daily prices are considered. A value of 30 or below may imply oversold and 70 or above may imply overbought.

**Price Volatility** - The standard deviation of the last 20 days of daily closing prices.

**Sharpe Ratio** - The 5 year average of the excess monthly return over the risk - free rate(1 - month T - bill) over the 5 year standard deviation of the same series.

**Sortino Ratio** - The same calculation as the Sharpe Ratio but with positive excess returns set to zero for the standard deviation denominator, so only negative volatility weighs in.

**Dividends Per Share TTM** - Sum of the last four quarters of Dividends Per Share.

**Payout Ratio** - Dividends Per Share TTM divided by Normalized EPS TTM.

**Dividend Yield TTM %** - Sum of the last four quarter of Dividends Per Share divided by Weekly Price.

**EBITDA** - Sum of the last four quarters of EBITDA (Operating Income + Depreciation & Amortization).

**Free Cash Flow** - Sum of the last four quarters Net Cash from Operations minus Capital Expenditures (Purchase of Property, Plant & Equipment), from the Cash Flow Statement.

**Book Value Per Share** - Total Common Equity last quarter divided by Shares Outstanding last quarter.

**Gross Margin %** - Sum of the last four quarters Gross Profit divided by the sum of the last four quarters Revenues.

**EBITDA Margin %** - Sum of the last four quarters EBITDA divided by the sum of the last four quarters Revenues.

**Pre-Tax Margin %** - Sum of the last four quarters of Earnings Before Taxes divided by sum of the last four quarters Revenues.

**Net Profit Margin %** - Sum of the last four quarters of Normalized EPS divided by sum of the last four quarters Revenues Per Share.

**Return on Equity %** - Sum of the last four quarters of Normalized EPS divided by the average of the last four quarters Book Value.

**Return on Capital %** - Sum of the last four quarters of Normalized EPS divided by the average of the last four quarters Total Capital Per Share.

**Return on Assets %** - Sum of the last four quarters of Normalized EPS divided by the average of the last four quarters Total Assets Per Share.

**Price / EPS TTM** - Weekly Price divided by the sum of the last four quarters of Normalized EPS (capped at 99.9).

**Price / Sales** - Weekly Price divided by Revenues Per Share TTM.

**Price / Book Value** - Weekly Price divided by Book Value Per Share last quarter. Book Value Per Share is Total Common Equity last quarter divided by Shares Outstanding last quarter (capped at 49.9).

**Free Cash Flow Yield %** - Free Cash Flow Per Share TTM divided by Weekly Price.

**Enterprise Value** - Market Value plus Total Debt last year plus Preferred Equity last year minus Cash & Cash Equivalents last year.

**Enterprise Value / Sales** - Enterprise Value divided by the sum of the last four quarters of Revenue.

**Enterprise Value / EBITDA** - Enterprise Value divided by EBITDA TTM.

**Enterprise Value / EBIT** - Enterprise Value divided by trailing four quarters of Operating Income.

**Enterprise Value / Free Cash Flow** - Enterprise Value divided by the sum of the last four quarters of Free Cash Flow.

**Russell 1000 Index** - The largest 1,000 stocks by market cap, the index comprehensively covers the US large cap universe.

EPS 5-Year Growth Rate % is capped at 999.9%.

Revenue 5-Year Growth Rate % is capped at 999.9%.

# Bioventix PLC (BVXP:LN)



Health Care/Biotechnology

Price: 16.75

Report Date: May 29, 2026

## Disclaimer:

© 2026 London Stock Exchange Group plc and its applicable group undertakings (the "LSE Group"). The LSE Group includes (1) FTSE International Limited ("FTSE"), (2) Frank Russell Company ("Russell"), (3) FTSE Global Debt Capital Markets Inc. and FTSE Global Debt Capital Markets Limited (together, "FTSE Canada"), (4) MTSNext Limited ("MTSNext"), (5) Mergent, Inc. ("Mergent"), (6) FTSE Fixed Income LLC ("FTSE FI") and (7) The Yield Book Inc ("YB"). All rights reserved.

FTSE Russell® is a trading name of FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB. "FTSE®", "Russell®", "FTSE Russell®", "MTS®", "FTSE4Good®", "ICB®", "Mergent®", "The Yield Book®" and all other trademarks and service marks used herein (whether registered or unregistered) are trademarks and/or service marks owned or licensed by the applicable member of the LSE Group or their respective licensors and are owned, or used under licence, by FTSE, Russell, MTSNext, FTSE Canada, Mergent, FTSE FI, YB. FTSE International Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator.

All information is provided for information purposes only. All information and data contained in this publication is obtained by the LSE Group, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error as well as other factors, however, such information and data is provided "as is" without warranty of any kind. No member of the LSE Group nor their respective directors, officers, employees, partners or licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the accuracy, timeliness, completeness, merchantability of any information or of results to be obtained from the use of FTSE Russell indexes or data or the fitness or suitability of the FTSE Russell indexes or data for any particular purpose to which they might be put. Any representation of historical data accessible through FTSE Russell indexes or data is provided for information purposes only and is not a reliable indicator of future performance.

No responsibility or liability can be accepted by any member of the LSE Group nor their respective directors, officers, employees, partners or licensors for (a) any loss or damage in whole or in part caused by, resulting from, or relating to any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analysing, editing, transcribing, transmitting, communicating or delivering any such information or data or from use of this document or links to this document or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if any member of the LSE Group is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, such information.

No member of the LSE Group nor their respective directors, officers, employees, partners or licensors provide investment advice and nothing contained in this document or accessible through FTSE Russell indexes or data, including statistical data and industry reports, should be taken as constituting financial or investment advice or a financial promotion.

No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the applicable member of the LSE Group. Use and distribution of the LSE Group data requires a licence from FTSE, Russell, FTSE Canada, MTSNext, Mergent, FTSE FI, YB, and/or their respective licensors.